Teva, Texas Enter $225M Opioid Settlement Agreement


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has reached a settlement worth $225 million to resolve claims the Company fueled an opioid epidemic in Texas.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

  • Texas Attorney General Ken Paxton said Teva agreed to pay $150 million over 15 years and provide $75 million worth of generic Narcan, a medication used to counter the effects of opioid overdoses.
  • Teva did not admit wrongdoing as part of Monday's settlement.
  • The Company will continue to defend itself in court in states where we have not reached a settlement agreement.
  • California judge in November concluded Teva and three other drugmakers could not be held responsible for causing the epidemic in several large counties in that state.
  • Price Action: TEVA shares are up 0.65% at $8.57 during the market session on the last check Monday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: BiotechNewsHealth CareLegalGeneralBriefs